Ventyx Biosciences (VTYX) Competitors $2.54 -0.20 (-7.30%) Closing price 04:00 PM EasternExtended Trading$2.58 +0.04 (+1.57%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VTYX vs. NAGE, PHAR, AVBP, SANA, GYRE, OCS, DNA, ATAI, IMTX, and TNGXShould you be buying Ventyx Biosciences stock or one of its competitors? The main competitors of Ventyx Biosciences include Niagen Bioscience (NAGE), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Sana Biotechnology (SANA), Gyre Therapeutics (GYRE), Oculis (OCS), Ginkgo Bioworks (DNA), atai Life Sciences (ATAI), Immatics (IMTX), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry. Ventyx Biosciences vs. Its Competitors Niagen Bioscience Pharming Group ArriVent BioPharma Sana Biotechnology Gyre Therapeutics Oculis Ginkgo Bioworks atai Life Sciences Immatics Tango Therapeutics Ventyx Biosciences (NASDAQ:VTYX) and Niagen Bioscience (NASDAQ:NAGE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership. Which has better earnings and valuation, VTYX or NAGE? Niagen Bioscience has higher revenue and earnings than Ventyx Biosciences. Ventyx Biosciences is trading at a lower price-to-earnings ratio than Niagen Bioscience, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVentyx BiosciencesN/AN/A-$135.12M-$1.68-1.51Niagen Bioscience$116.30M6.88$8.55M$0.2147.76 Which has more risk & volatility, VTYX or NAGE? Ventyx Biosciences has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Comparatively, Niagen Bioscience has a beta of 2.12, meaning that its share price is 112% more volatile than the S&P 500. Does the media favor VTYX or NAGE? In the previous week, Ventyx Biosciences and Ventyx Biosciences both had 2 articles in the media. Niagen Bioscience's average media sentiment score of 0.18 beat Ventyx Biosciences' score of 0.00 indicating that Niagen Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ventyx Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Niagen Bioscience 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Is VTYX or NAGE more profitable? Niagen Bioscience has a net margin of 15.24% compared to Ventyx Biosciences' net margin of 0.00%. Niagen Bioscience's return on equity of 23.12% beat Ventyx Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ventyx BiosciencesN/A -48.89% -44.87% Niagen Bioscience 15.24%23.12%15.53% Do analysts rate VTYX or NAGE? Ventyx Biosciences currently has a consensus price target of $7.50, suggesting a potential upside of 195.28%. Niagen Bioscience has a consensus price target of $13.42, suggesting a potential upside of 33.80%. Given Ventyx Biosciences' higher probable upside, research analysts plainly believe Ventyx Biosciences is more favorable than Niagen Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ventyx Biosciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Niagen Bioscience 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in VTYX or NAGE? 97.9% of Ventyx Biosciences shares are held by institutional investors. Comparatively, 15.4% of Niagen Bioscience shares are held by institutional investors. 18.2% of Ventyx Biosciences shares are held by insiders. Comparatively, 9.4% of Niagen Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryNiagen Bioscience beats Ventyx Biosciences on 11 of the 14 factors compared between the two stocks. Get Ventyx Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for VTYX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VTYX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTYX vs. The Competition Export to ExcelMetricVentyx BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$181.13M$3.06B$5.76B$9.72BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-1.5120.9030.1925.84Price / SalesN/A386.36473.64122.75Price / CashN/A43.2325.7828.79Price / Book0.719.649.425.99Net Income-$135.12M-$54.08M$3.27B$265.29M7 Day Performance-10.25%2.62%2.05%2.53%1 Month Performance-20.13%4.05%3.58%0.93%1 Year Performance12.39%9.48%30.09%18.70% Ventyx Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTYXVentyx Biosciences2.1959 of 5 stars$2.54-7.3%$7.50+195.3%+21.2%$181.13MN/A-1.5130NAGENiagen Bioscience1.164 of 5 stars$10.12+1.0%$13.42+32.6%N/A$799.13M$116.30M48.19120Analyst DowngradePHARPharming Group2.4345 of 5 stars$12.39+6.4%$30.00+142.1%+81.2%$798.20M$297.20M-95.31280Gap UpAVBPArriVent BioPharma2.3093 of 5 stars$19.24-1.5%$39.14+103.4%-17.1%$792.31MN/A-4.7940SANASana Biotechnology2.9427 of 5 stars$3.40+2.1%$8.00+135.3%-38.7%$791.90MN/A-3.21380GYREGyre Therapeutics0.0294 of 5 stars$7.85-3.6%N/A-36.3%$783.99M$102.19M785.7940OCSOculis2.9871 of 5 stars$18.06+0.9%$35.33+95.6%+49.6%$781.56M$780K-6.842News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst ForecastDNAGinkgo Bioworks1.3378 of 5 stars$13.79+4.6%$8.50-38.4%+53.5%$780.25M$227.04M-2.35640Analyst ForecastATAIatai Life Sciences3.5735 of 5 stars$4.05+4.4%$11.25+177.8%+248.9%$777.31M$310K-5.8780Gap UpIMTXImmatics1.8838 of 5 stars$6.21-1.9%$14.67+136.2%-49.2%$769.41M$168.65M-9.55260Gap DownHigh Trading VolumeTNGXTango Therapeutics1.6082 of 5 stars$7.22+6.6%$10.33+43.1%-40.4%$753.23M$42.07M-5.4390 Related Companies and Tools Related Companies Niagen Bioscience Competitors Pharming Group Competitors ArriVent BioPharma Competitors Sana Biotechnology Competitors Gyre Therapeutics Competitors Oculis Competitors Ginkgo Bioworks Competitors atai Life Sciences Competitors Immatics Competitors Tango Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VTYX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ventyx Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ventyx Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access